HC Wainwright & Co. Maintains Buy on Ascendis Pharma, Lowers Price Target to $344

Benzinga Newsdesk www.benzinga.com Negative 72.2%

Neg 72.2% Neu 0% Pos 0%

HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Ascendis Pharma (NASDAQ:ASND) with a Buy and lowers the price target from $345 to $344.